Latest news with #EU-GMP
Cision Canada
14-07-2025
- Business
- Cision Canada
Aurora Completes First-Ever EU-GMP Certification for the Company's Dedicated Distribution Centre
Adding a fourth certified facility within its global network increases operational capacity to better serve international medical markets NASDAQ| TSX: EDMONTON, AB, July 14, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that its dedicated distribution centre located in Brampton, Ontario, has received European Union Good Manufacturing Practice ("EU-GMP") certification, increasing the company's international export capabilities. The distribution centre joins Aurora's group of manufacturing facilities in Canada and Europe certified against EU standards, demonstrating the company's unwavering commitment to regulatory excellence, end-to-end operational quality assurance, and global supply chain efficiency. "Securing EU-GMP certification at manufacturing and distribution facilities within our network is an important validation of our differentiated approach to operating as a global medical cannabis company," said Jill Lau, Vice President of Canadian Operations at Aurora. "By adding certification for our distribution centre, we are now uniquely positioned to ensure patients worldwide have consistent access to superior quality medical cannabis from the largest Canadian exporter." EU-GMP certification is granted to companies whose production facilities meet the requirements under the EudraLex "Rules Governing Medicinal Products in the European Union," and that can demonstrate a high degree of quality and consistency in their manufacturing procedures, a requirement for the export of medical cannabis products into Europe. EU-GMP certification of the company's distribution centre allows it to serve as a centralized site for more optimized and efficient receipt, storage and distribution of materials and finished products internationally. With operations across Canada and in Europe, Aurora remains at the forefront of the global medical cannabis industry. By continuously investing in operational capabilities, regulatory excellence, and a science-led approach, Aurora is best positioned to deliver high-quality medical cannabis that meets and exceeds the highest international standards. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the EU-GMP certification for the Company's dedicated distribution centre and benefits for the Company, including increases to operational capacity for international medical markets; statements regarding the Company's ability to meet patient demand globally; and the Company's commitment to regulatory excellence, end-to-end operational quality assurance and global supply chain efficiency. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. SOURCE Aurora Cannabis Inc.
Cision Canada
03-07-2025
- Business
- Cision Canada
Blue Sky Hemp Ventures Sells Hemp Food Division to Fresh Hemp Foods to Focus on Cannabis Extracts and Contract Manufacturing
SASKATOON, SK, July 3, 2025 /CNW/ - Blue Sky Hemp Ventures Ltd. ("Blue Sky"), a privately held Canadian company founded in 2017 and a pioneer in industrial hemp whole plant utilization, has sold its hemp-based food division to Fresh Hemp Foods, a major hemp food company, for an undisclosed amount. "Thanks to a differentiated strategy and disciplined execution, Blue Sky has delivered two consecutive years of positive EBITDA and net earnings—an uncommon achievement in this sector," said CEO Andrew Potter. "After strong growth in both our food and cannabis divisions, we reached a strategic crossroads. With limited physical space and capital, we concluded that monetizing our successful hemp food business would allow us to better scale our cannabis operations and drive long-term shareholder value." Proceeds from the sale will be used to accelerate expansion of Blue Sky's contract manufacturing services—including vape pens, pre-rolls, and softgels—building on its strong foundation in topicals and oils. The company is also on track to complete EU-GMP certification, unlocking new global opportunities for bulk extracts and finished products. "Although we had limited resources, our team successfully built a high-growth, EBITDA positive food business over the last few years. I'm incredibly proud of our product innovation, particularly our refined hemp seed oil—an excellent example of our ability to cost-effectively develop new products," said Potter. "This spirit of innovation will continue to drive our cannabis operations. We're confident the purchaser of our food operation will take this food business to the next level, and we look forward to supporting them." "We welcome Blue Sky's customers and suppliers to Fresh Hemp Foods. Blue Sky has championed whole plant utilization, and we intend to carry that forward alongside our own industry leading sustainability efforts. Fresh Hemp Foods remains focused on bringing nutritious, sustainable hemp foods to more and more customers and consumers," said Jared Simon, President, Manitoba Harvest and Tilray Wellness. About Blue Sky Hemp Ventures Founded in 2017, Blue Sky operates a 15,000 sq ft cannabis processing facility in Saskatoon, Saskatchewan. Following its latest expansion (completed December 2024), Blue Sky is one of the largest independent extractors in Canada, processing approximately 20,000 kg of dry cannabis flower per month. The company now operates two core divisions: Bulk Cannabinoid Extraction and Refinement Contract Manufacturing – including oils, topicals, and new offerings such as vapes, prerolls and softgels. Over the coming months, Blue Sky will continue to convert its facility to full EU-GMP compliance to support global manufacturing and extraction partnerships.
The Market Online
24-06-2025
- Business
- The Market Online
Tilray sets medical cannabis milestone in Italy
Tilray Medical, a division of Tilray Brands (TSX:TLRY), has become the first company to receive Italian authorization to distribute medical cannabis flower for therapeutic use Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment Tilray stock has given back 78.17 per cent year-over-year and 97.46 per cent since 2021 Tilray Medical, a division of major cannabis player Tilray Brands (TSX:TLRY), has become the first company to receive authorization from Italy's Ministero della Salute to distribute medical cannabis flower for therapeutic use. Tilray Medical, operating through wholly-owned subsidiary, FL Group, will introduce three new medical cannabis flower varieties to Italy beginning in June, which will be available for distribution through pharmacies across the country. They are: Tilray THC 25%. Tilray THC 18%. Tilray THC 9% / CBD 9%. The approval complements Tilray's existing presence in Italy, initially announced in May 2023, as well as its leading position in the European market, including operations in Germany, Portugal, Poland and the United Kingdom. Leadership insights 'This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being. We are proud to expand our medical cannabis portfolio in Italy with the introduction of our Tilray Medical high-quality, EU-GMP certified medical cannabis products that uphold the highest standards in patient care,' Denise Faltischek, Tilray Brands' chief strategy officer and head of international, said in a statement. 'We extend our gratitude to the Ministero della Salute for their trust in Tilray Medical and for providing the necessary regulatory framework to ensure access to safe, consistent and reliable cannabinoid-based therapies. Together, we are advancing healthcare and patient wellness through innovation and collaboration.' About Tilray Brands Tilray is a global consumer packaged goods company active in cannabis, beverage, wellness and entertainment. The company's platform includes more than 40 brands spanning presences in more than 20 countries. Tilray stock (TSX:TLRY) last traded at C$0.50. The stock has given back 78.17 per cent year-over-year and 97.46 per cent since 2021. Join the discussion: Find out what investors are saying about this cannabis stock's expansion in Italy on the Tilray Brands Inc. Bullboard, and make sure to check out the rest of Stockhouse's stock forums and message boards. The material provided in this podcast is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Business Wire
24-06-2025
- Business
- Business Wire
Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer
LONDON--(BUSINESS WIRE)--The Bloom Brand, a recognized U.S. leader in cannabis vape, is making its international debut in the United Kingdom through an exclusive partnership with New Garden Pharma, a leading European EU-GMP cannabis operator. Together, the two companies will launch Bloom's award-winning Classic and Live vape collections in the UK in Q1 2026. Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer. Share This marks Bloom's first international market expansion, as the company continues its global growth strategy with additional EU markets in development for 2026 and beyond. UK patients will gain access to Bloom's superior formulations and proprietary hardware systems. For more than a decade, Bloom has built its reputation on delivering terpene-rich, flavor-forward strains paired with reliable technology. The brand has an established and leading presence across leading U.S. markets including California, Illinois, Florida, Michigan, Missouri, New Jersey, New Mexico, New York, and Virginia. 'Expanding into the UK is a pivotal step towards our mission to reshape the global cannabis experience,' said Ovidiu (David) Chiorpec, Director of Business Development at Bloom. 'We've spent over a decade building a brand that patients trust in the U.S., and we're excited to introduce the UK consumer to a new level of excellence and sophistication in the vape category.' New Garden Pharma, medical subsidiary of New Garden Group, is a trusted name in European cannabis manufacturing who combines a unique supply chain model with a proven track record in regulatory compliance and market expansion. With established infrastructure across the continent, the company will lead Bloom's UK entry — ensuring a compliant, efficient, and scalable launch across all channels. 'We're excited to welcome Bloom to the UK market,' said Alexey Brylev, CEO of New Garden Group. 'As an established operator across European medical cannabis markets, we bring the EU-GMP manufacturing expertise, local insight, and regulatory know-how needed to help global brands thrive. This partnership reflects our broader mission: to deliver world-class products to European patients and to raise the bar for quality, safety, and innovation across the continent.'
Entrepreneur
13-06-2025
- Business
- Entrepreneur
Entrepreneur UK's London 100: Mamedica
Mamedica is a private clinic with a linked pharmacy specialising in cannabis-based prescriptions (from oil to cannabis flower) Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Industry: Health and wellness Mamedica is a private clinic with a linked pharmacy specialising in cannabis-based prescriptions (from oil to cannabis flower). In the last year alone, they experienced a 2,000% revenue increase and a 675,000% growth since inception in their patient base, reflecting the urgent need for alternative treatments. Founded by Jon Robson, and launched in 2022, Mamedica aims to deliver a quality of service which is currently lacking in the medical cannabis sector. Mamedica puts patient safety, security, and satisfaction at the forefront of every activity, using only the most high-calibre consultants and support staff as part of their team. Following a secure, private video consultation the medicines can be delivered directly to the patient's door via next-day delivery service. All medications prescribed by Mamedica are produced and manufactured according to the pharmaceutical-grade EU-GMP (Good Manufacturing Practice), the most stringent in the world. Patients can be assured that their medicines are not contaminated with pesticides or adulterants. The medical cannabis market currently has north of 50,000 patients in the market - expected to rise to 300,000 plus by 2028. The UK's medical cannabis market was valued at approximately £188m in 2023 and is projected to exceed £470m by 2027. Around 60% of their patients seek treatment for psychological or neurological conditions, while 40% present with pain-related issues. The most common conditions they support include anxiety (21%), depression (13%), chronic pain (12%), back and neck pain (10%), and ADHD (10%).
